Bo Anders Ljungqvist

Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019.

Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019.

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.

Invest AD Asset Management PJSC (Invest AD) is the sovereign wealth manager of government-owned Abu Dhabi Investment Council. The firm was founded in 1977 and is headquartered in Abu Dhabi. Invest AD provides asset management services to international high-net worth individuals and institutions.